Russell 2000 Index Newsroom

B of A Securities Initiates Coverage On KalVista Pharma With Buy Rating, Announces Price Target of $22

Benzinga2minutes ago · Ratings

Academy Sports Analyst Ratings

Benzinga10minutes ago · Ratings

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

Benzinga12minutes ago

Fluor Analyst Ratings

Benzinga13minutes ago · Ratings

Barclays Upgrades Transocean to Overweight, Maintains Price Target to $4.5

Benzinga14minutes ago · Ratings

Forecasting The Future: 12 Analyst Projections For Fluence Energy

Benzinga15minutes ago

Transocean Analyst Ratings

Benzinga15minutes ago · Ratings

Oceaneering International Analyst Ratings

Benzinga18minutes ago · Ratings

Valaris Analyst Ratings

Benzinga24minutes ago · Ratings

Krystal Biotech Analyst Ratings

Benzinga29minutes ago · Ratings

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index

Benzinga44minutes ago

Getty Images Holdings Analyst Ratings

Benzinga44minutes ago · Ratings

ALX Oncology Holdings Analyst Ratings

Benzinga45minutes ago · Ratings

Needham Reiterates Buy on Foot Locker, Maintains $25 Price Target

Benzinga56minutes ago · Ratings

Foot Locker Analyst Ratings

Benzinga59minutes ago · Ratings

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target

Benzinga59minutes ago · Ratings

Halozyme Therapeutics Analyst Ratings

Benzinga19:14 · Ratings

Kosmos Energy Analyst Ratings

Benzinga19:14 · Ratings

HC Wainwright & Co. Reiterates Buy on RCI Hospitality Hldgs, Maintains $98 Price Target

Benzinga19:11 · Ratings

RCI Hospitality Hldgs Analyst Ratings

Benzinga19:09 · Ratings